|
|
Post by dh4mizzou on May 31, 2018 12:12:32 GMT -5
DBC, Perhaps if we could get Apple involved? ;-)
|
|
|
|
Post by mango on May 31, 2018 12:45:20 GMT -5
This is the MannKind Inventors Consensus Statement (😉) behind the rationale for this patent/invention:
Present systems and methods for measuring the resistance to air flow through an inhaler are cumbersome, involve numerous steps and calculations and are subject to variations in ambient conditions. Therefore, the inventors have seen the need to design and manufacture a simple apparatus, system, and method for measuring the resistance to airflow of an inhaler in order to determine if the inhaler resistance properties would render the inhaler suitable for use. The present system allows for a rapid method for measuring the resistance of inhalation systems or the individual inhalers, in an integrated system using a few simple steps.
|
|
|
|
Post by dreamboatcruise on May 31, 2018 13:21:07 GMT -5
It should be noted that the patent this thread is about actually has nothing to do with Bluhale. That was a bit off topic.
|
|
|
|
Post by dreamboatcruise on May 31, 2018 13:23:09 GMT -5
DBC, Perhaps if we could get Apple involved? ;-) Yes, maybe the iPhone XX will have an inhalation device built into it. I hear all sorts of rumors about what will be included in the iPhone XXX. |
|
|
|
Post by mango on May 31, 2018 13:28:48 GMT -5
It should be noted that the patent this thread is about actually has nothing to do with Bluhale. That was a bit off topic.  |
|
|
|
Post by mango on Jul 7, 2018 14:52:08 GMT -5
New International MannKind Patent Application Published July 5, 2018 Application Date: 02.03.2018 Publication Date: 05.07.2018 Applicants: MannKind Corporation Inventors: Peter Richardson Robert A. Baughman Elizabeth Potocka Anders Hasager Boss Richard Petrucci Title: (EN) METHOD OF TREATING DIABETES TYPE 2 BY ADMINISTERING ULTRARAPID ACTING INSULIN Abstract: (EN) Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. patentscope.wipo.int/search/en/detail.jsf?docId=US222841891 |
|
|
|
Post by mango on Jul 8, 2018 10:55:40 GMT -5
|
|
|
|
Post by brotherm1 on Jul 8, 2018 19:11:48 GMT -5
Interesting. Could this be in preparation for when Afrezza might be labeled ultra rapid? Would such a patent almost put the kibosh on Dance’s inhaled insulin in case it would someday be approved?
|
|
|
|
Post by mango on Jul 15, 2018 22:51:51 GMT -5
New International MannKind Patent Application Published July 12, 2018 REACTOR FOR PRODUCING PHARMACEUTICAL PARTICLES IN A PRECIPITATION PROCESSAbstract: Reactors, reactor systems and methods for producing particles in a precipitation process are provided. The reactor includes a housing defining a reaction chamber, a stator assembly including two or more stators, a rotor assembly including two or more rotors, the rotor assembly configured for rotation about an axis of rotation relative to the stator assembly, a first inlet to supply a first reactant material to the reaction chamber at a first radial location, a second inlet to supply a second reactant material to the reaction chamber at a second radial location different from the first radial location, wherein the first and second reactant materials react to produce precipitation of particles in the reaction chamber, and an outlet to supply the particles formed in the reaction chamber. Type: Application Filed: March 7, 2018 Publication date: July 12, 2018 Applicant: Mannkind Corporation Inventors: Sanket Gandhi, Karen Moraleda, Jadwiga Jachowicz, Michael Zupon patents.justia.com/patent/20180193813patentscope.wipo.int/search/en/detail.jsf?docId=US222922118&recNum=1&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1111 |
|
|
|
Post by matt on Jul 16, 2018 8:42:54 GMT -5
Would such a patent almost put the kibosh on Dance’s inhaled insulin in case it would someday be approved? Unlikely, very unlikely. In order for a utility patent to be valid it must describe something that is novel, useful, and not obvious to someone skilled in the art (all three factors must be met). Afrezza is an inhaled insulin, but it was hardly the first to come to market and any physician skilled in treating diabetics might logically decide that an inhaled insulin is an option worth trying. Further, this patent does not describe a novel composition of matter (patent lawyer speak for a new molecule) so this is not a utility patent at all but rather a process patent. Process patents prevent someone else from using something for a particular described use. In theory, if MNKD developed a suitable protocol for improving glucose control using Afrezza then Dance could not promote the exact same protocol for use with their insulin. However, a physician that was aware of the MNKD process could decide to use it and substitute a competitor's product, and this happens all the time in healthcare. Similarly, a physician could run a small medical study to show that the protocol when used with Afrezza gives essentially the same results as the protocol when used with the Dance product. Once that kind of information is published in a medical journal, the genie is out of the bottle. A company holding a process patent on a medical treatment has the unenviable task of choosing between nonenforcement of the patent, or enforcement of the patent by suing physicians and hospitals. Process patents are useful if the company is a manufacturer and there are a handful of competitors trying to use a proprietary manufacturing method, but imagine the surveillance task of following the prescribing habits of thousands of endocrinologists and primary care physicians to detect potential infringers. In the end, suing your customer is never a good way to drive adoption of your product. |
|
|
|
Post by babaoriley on Jul 16, 2018 12:22:02 GMT -5
Patents are absolutely necessary, but more so as a shield; when it comes time to use them as a sword, they rarely do you any good other than to distract management and make a lot of money for patent litigators.
|
|
|
|
Post by rockstarrick on Jul 17, 2018 10:36:18 GMT -5
Interesting. Could this be in preparation for when Afrezza might be labeled ultra rapid? Would such a patent almost put the kibosh on Dance’s inhaled insulin in case it would someday be approved? I believe Dance Pharmas Inhaled Insulin is a liquid, (it was in 2014 when Dance surfaced after the dreaded 90 day delay of Afrezza), the liquid is converted to a mist via nebulizer. The problem with this, was some of the mist covered the throat and mouth area, never making it into the lung where it could be adsorbed into the blood system. The difference between Dances product and Afrezza, is the process of coatinging our Insulin with the FDKP particles is an adsorption process which is controlled by pH, and reversible only when it comes in contact with the lungs, or a pH near neutral, or 7. the significance of this, is any product that doesn’t reach the lungs pH of 7, remain coated in the FDKP particles and isn’t adsorbed as Insulin. This ensures the only product that effects the blood sugars is the product that reaches the lung. at least this is how I understand it, I’m sure there are a few on here that will be more familiar with the actual adsorption process, and how this chemical reaction is reversible by pH. Dance is a non issue in my opinion. ✌🏻😎 |
|
|
|
Post by mango on Aug 20, 2018 20:01:21 GMT -5
Been away at concerts & music festivals...was a nice break, but I’m back yeah. New MannKind Granted Patent 8/14/18 Use of ultrarapid acting insulinAbstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day. Type: Grant Filed: February 1, 2017 Date of Patent: August 14, 2018 Assignee: MannKind Corporation Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann patents.justia.com/patent/10046031 |
|
|
|
Post by mango on Aug 20, 2018 20:20:34 GMT -5
Saw mnholdem already posted this but just making note in here for it, plus an additional international patent application published on the same date. Two New International MannKind Patent Applications Published 8/9/2018 Application Date: 31.01.2018 Publication Date: 09.08.2018 Applicants: MannKind Corporation Inventors: Karine Fabio Joseph J. Guarneri Kieran Curley Marshall L. Grant Andrea Leone-Bay Title: (EN) HEAT-STABLE DRY POWDER PHARMACEUTICAL COMPOSITIONS AND METHODS Abstract: (EN) Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution. patentscope.wipo.int/search/en/detail.jsf?docId=US224374923&recNum=1&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1115Application Date: 27.01.2017 Publication Date: 09.08.2018 Applicants: MannKind Corporation Inventors:Title: (EN) Dry powder inhaler Abstract: (EN) A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation. patentscope.wipo.int/search/en/detail.jsf?docId=AU224539195&recNum=2&office=&queryString=FP%3A%28MannKind%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=1115 |
|
|
|
Post by sayhey24 on Aug 20, 2018 21:05:38 GMT -5
Is the new patent "Use of ultrarapid acting insulin" patents.justia.com/patent/10046031 enough to get Dr. Kendall some movement on getting changes to both the T1 and T2 standard of care? |
|
